Skip to content
Biodatica
Start free

Bio-Thera Solutions

Wuhan, Hubei

OncologyantibodyPhase III
Compare Sign in to watch

What changed

Phase III trial registered: INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

2mo agoTrial registeredMay 18, 2026Source filing (opens the source filing in a new tab)

Momentum

75no change

Momentum 75 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

604 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Nov 27, 2025

    Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Carcinoma, High-grade Serous Ovarian Cancer · NOT_YET_RECRUITING · sponsor: Tongji Hospital · Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance

    ClinicalTrials.gov · NCT07269574 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Nov 15, 2025

    Ovarian Clear Cell Carcinoma · RECRUITING · sponsor: Tongji Hospital · INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

    ClinicalTrials.gov · NCT07002346 (opens the source filing in a new tab)

  3. Trial

    PHASE2/PHASE3 registered

    Dec 13, 2023

    Cervical Cancer · RECRUITING · sponsor: Bio-Thera Solutions · BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

    ClinicalTrials.gov · NCT06123884 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources